| 000 | 01120 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250513225206.0 | ||
| 264 | 0 | _c20010802 | |
| 008 | 200108s 0 0 eng d | ||
| 022 | _a0041-1345 | ||
| 024 | 7 |
_a10.1016/s0041-1345(00)01339-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHolt, D W | |
| 245 | 0 | 0 |
_aThe impact of cyclosporin formulation on clinical outcomes. _h[electronic resource] |
| 260 |
_bTransplantation proceedings _cNov 2000 |
||
| 300 |
_a1552-5 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aChemistry, Pharmaceutical |
| 650 | 0 | 4 |
_aCyclosporine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Transplantation _ximmunology |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aJohnston, A | |
| 773 | 0 |
_tTransplantation proceedings _gvol. 32 _gno. 7 _gp. 1552-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0041-1345(00)01339-7 _zAvailable from publisher's website |
| 999 |
_c11060447 _d11060447 |
||